Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

RERE vs BACK vs EBAY vs ATXI vs XTLB

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
RERE
ATRenew Inc.

Specialty Retail

Consumer CyclicalNYSE • CN
Market Cap$1.10B
5Y Perf.-69.8%
BACK
IMAC Holdings, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$78K
5Y Perf.-99.9%
EBAY
eBay Inc.

Specialty Retail

Consumer CyclicalNASDAQ • US
Market Cap$48.63B
5Y Perf.+51.6%
ATXI
Avenue Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$2M
5Y Perf.-100.0%
XTLB
XTL Biopharmaceuticals Ltd.

Biotechnology

HealthcareNASDAQ • IL
Market Cap$294K
5Y Perf.-83.3%

RERE vs BACK vs EBAY vs ATXI vs XTLB — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
RERE logoRERE
BACK logoBACK
EBAY logoEBAY
ATXI logoATXI
XTLB logoXTLB
IndustrySpecialty RetailMedical - Care FacilitiesSpecialty RetailBiotechnologyBiotechnology
Market Cap$1.10B$78K$48.63B$2M$294K
Revenue (TTM)$18.54B$23K$11.60B$1M$451K
Net Income (TTM)$210M$-10M$2.04B$-4M$-1M
Gross Margin20.5%-18.4%72.0%100.0%26.4%
Operating Margin1.3%-398.1%19.6%-279.8%-481.6%
Forward P/E1.5x17.4x
Total Debt$355M$0.00$7.38B$0.00$138K
Cash & Equiv.$1.97B$504K$1.87B$3M$371K

RERE vs BACK vs EBAY vs ATXI vs XTLBLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

RERE
BACK
EBAY
ATXI
XTLB
StockJun 21May 26Return
ATRenew Inc. (RERE)10030.2-69.8%
IMAC Holdings, Inc. (BACK)1000.1-99.9%
eBay Inc. (EBAY)100151.6+51.6%
Avenue Therapeutics… (ATXI)1000.0-100.0%
XTL Biopharmaceutic… (XTLB)10016.7-83.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: RERE vs BACK vs EBAY vs ATXI vs XTLB

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: RERE and BACK are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. IMAC Holdings, Inc. is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. EBAY and ATXI also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
RERE
ATRenew Inc.
The Growth Play

RERE has the current edge in this matchup, primarily because of its strength in growth exposure and sleep-well-at-night.

  • Rev growth 25.9%, EPS growth 94.7%, 3Y rev CAGR 28.0%
  • Lower volatility, beta 1.36, Low D/E 9.6%, current ratio 3.19x
  • 25.9% revenue growth vs XTLB's -173.2%
  • Better valuation composite
Best for: growth exposure and sleep-well-at-night
BACK
IMAC Holdings, Inc.
The Income Pick

BACK is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.

  • Dividend streak 1 yrs, beta 0.05, yield 100.0%
  • Beta 0.05, yield 100.0%, current ratio 0.09x
  • Beta 0.05 vs XTLB's 1.71
  • 100.0% yield, 1-year raise streak, vs EBAY's 1.1%, (3 stocks pay no dividend)
Best for: income & stability and defensive
EBAY
eBay Inc.
The Long-Run Compounder

EBAY ranks third and is worth considering specifically for long-term compounding.

  • 369.5% 10Y total return vs RERE's -73.2%
  • 17.6% margin vs BACK's -426.9%
  • 11.5% ROA vs BACK's -31.3%
Best for: long-term compounding
ATXI
Avenue Therapeutics, Inc.
The Momentum Pick

ATXI is the clearest fit if your priority is momentum.

  • +150.1% vs XTLB's -50.9%
Best for: momentum
XTLB
XTL Biopharmaceuticals Ltd.
The Healthcare Pick

Among these 5 stocks, XTLB doesn't own a clear edge in any measured category.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthRERE logoRERE25.9% revenue growth vs XTLB's -173.2%
ValueRERE logoREREBetter valuation composite
Quality / MarginsEBAY logoEBAY17.6% margin vs BACK's -426.9%
Stability / SafetyBACK logoBACKBeta 0.05 vs XTLB's 1.71
DividendsBACK logoBACK100.0% yield, 1-year raise streak, vs EBAY's 1.1%, (3 stocks pay no dividend)
Momentum (1Y)ATXI logoATXI+150.1% vs XTLB's -50.9%
Efficiency (ROA)EBAY logoEBAY11.5% ROA vs BACK's -31.3%

RERE vs BACK vs EBAY vs ATXI vs XTLB — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

REREATRenew Inc.
FY 2024
Product
90.9%$14.8B
Service
9.1%$1.5B
BACKIMAC Holdings, Inc.

Segment breakdown not available.

EBAYeBay Inc.
FY 2025
Marketplaces
82.0%$9.1B
Advertising Revenues
18.0%$2.0B
ATXIAvenue Therapeutics, Inc.

Segment breakdown not available.

XTLBXTL Biopharmaceuticals Ltd.

Segment breakdown not available.

RERE vs BACK vs EBAY vs ATXI vs XTLB — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLEBAYLAGGINGXTLB

Income & Cash Flow (Last 12 Months)

EBAY leads this category, winning 3 of 6 comparable metrics.

RERE is the larger business by revenue, generating $18.5B annually — 815762.1x BACK's $22,723. EBAY is the more profitable business, keeping 17.6% of every revenue dollar as net income compared to BACK's -426.9%. On growth, RERE holds the edge at +32.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricRERE logoREREATRenew Inc.BACK logoBACKIMAC Holdings, In…EBAY logoEBAYeBay Inc.ATXI logoATXIAvenue Therapeuti…XTLB logoXTLBXTL Biopharmaceut…
RevenueTrailing 12 months$18.5B$22,723$11.6B$1M$451,000
EBITDAEarnings before interest/tax$501M-$9M$2.6B-$4M-$1M
Net IncomeAfter-tax profit$210M-$10M$2.0B-$4M-$1M
Free Cash FlowCash after capex$0-$5M$1.7B-$2M$0
Gross MarginGross profit ÷ Revenue+20.5%-18.4%+72.0%+100.0%+26.4%
Operating MarginEBIT ÷ Revenue+1.3%-398.1%+19.6%-2.8%-4.8%
Net MarginNet income ÷ Revenue+1.1%-426.9%+17.6%-2.7%-2.3%
FCF MarginFCF ÷ Revenue+3.6%-215.1%+14.5%-124.1%-3.7%
Rev. Growth (YoY)Latest quarter vs prior year+32.2%-62.3%+19.5%
EPS Growth (YoY)Latest quarter vs prior year+5.4%+26.3%+5.7%+89.1%+20.0%
EBAY leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

RERE leads this category, winning 5 of 6 comparable metrics.

On an enterprise value basis, RERE's 16.1x EV/EBITDA is more attractive than EBAY's 21.0x.

MetricRERE logoREREATRenew Inc.BACK logoBACKIMAC Holdings, In…EBAY logoEBAYeBay Inc.ATXI logoATXIAvenue Therapeuti…XTLB logoXTLBXTL Biopharmaceut…
Market CapShares × price$1.1B$77,541$48.6B$2M$293,767
Enterprise ValueMkt cap + debt − cash$858M-$426,648$54.1B-$842,479$60,767
Trailing P/EPrice ÷ TTM EPS-907.40x-0.00x24.52x-0.61x-0.28x
Forward P/EPrice ÷ next-FY EPS est.1.46x17.40x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple16.11x21.03x
Price / SalesMarket cap ÷ Revenue0.46x1.08x4.38x0.65x
Price / BookPrice ÷ Book value/share2.02x10.61x3.84x0.05x
Price / FCFMarket cap ÷ FCF12.79x29.28x
RERE leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

EBAY leads this category, winning 4 of 9 comparable metrics.

EBAY delivers a 44.1% return on equity — every $100 of shareholder capital generates $44 in annual profit, vs $-161 for ATXI. XTLB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to EBAY's 1.60x. On the Piotroski fundamental quality scale (0–9), RERE scores 7/9 vs BACK's 1/9, reflecting strong financial health.

MetricRERE logoREREATRenew Inc.BACK logoBACKIMAC Holdings, In…EBAY logoEBAYeBay Inc.ATXI logoATXIAvenue Therapeuti…XTLB logoXTLBXTL Biopharmaceut…
ROE (TTM)Return on equity+5.5%+44.1%-160.6%-25.5%
ROA (TTM)Return on assets+4.0%-31.3%+11.5%-105.8%-17.7%
ROICReturn on invested capital+1.0%+16.8%-54.1%
ROCEReturn on capital employed+0.8%+17.4%-9.0%-50.7%
Piotroski ScoreFundamental quality 0–971623
Debt / EquityFinancial leverage0.10x1.60x0.03x
Net DebtTotal debt minus cash-$1.6B-$504,189$5.5B-$3M-$233,000
Cash & Equiv.Liquid assets$2.0B$504,189$1.9B$3M$371,000
Total DebtShort + long-term debt$355M$0$7.4B$0$138,000
Interest CoverageEBIT ÷ Interest expense23.67x-28.20x10.52x-13.31x
EBAY leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

EBAY leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in EBAY five years ago would be worth $18,633 today (with dividends reinvested), compared to $1 for ATXI. Over the past 12 months, ATXI leads with a +150.1% total return vs XTLB's -50.9%. The 3-year compound annual growth rate (CAGR) favors EBAY at 33.4% vs ATXI's -80.7% — a key indicator of consistent wealth creation.

MetricRERE logoREREATRenew Inc.BACK logoBACKIMAC Holdings, In…EBAY logoEBAYeBay Inc.ATXI logoATXIAvenue Therapeuti…XTLB logoXTLBXTL Biopharmaceut…
YTD ReturnYear-to-date-14.8%-69.7%+22.6%-19.8%+11.3%
1-Year ReturnPast 12 months+97.4%+19.4%+54.2%+150.1%-50.9%
3-Year ReturnCumulative with dividends+113.9%-99.2%+137.4%-99.3%-45.7%
5-Year ReturnCumulative with dividends-73.2%-99.9%+86.3%-100.0%-80.4%
10-Year ReturnCumulative with dividends-73.2%-100.0%+369.5%-100.0%-87.3%
CAGR (3Y)Annualised 3-year return+28.8%-80.2%+33.4%-80.7%-18.4%
EBAY leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — EBAY and ATXI each lead in 1 of 2 comparable metrics.

ATXI is the less volatile stock with a -0.11 beta — it tends to amplify market swings less than XTLB's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EBAY currently trades 95.5% from its 52-week high vs BACK's 18.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricRERE logoREREATRenew Inc.BACK logoBACKIMAC Holdings, In…EBAY logoEBAYeBay Inc.ATXI logoATXIAvenue Therapeuti…XTLB logoXTLBXTL Biopharmaceut…
Beta (5Y)Sensitivity to S&P 5001.36x0.05x0.73x-0.11x1.71x
52-Week HighHighest price in past year$6.47$0.21$111.38$0.97$10.28
52-Week LowLowest price in past year$2.34$0.03$67.87$0.15$1.05
% of 52W HighCurrent price vs 52-week peak+69.9%+18.2%+95.5%+56.7%+26.0%
RSI (14)Momentum oscillator 0–10039.940.263.154.657.0
Avg Volume (50D)Average daily shares traded1.1M3K5.4M3K2.4M
Evenly matched — EBAY and ATXI each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — BACK and EBAY each lead in 1 of 2 comparable metrics.

Analyst consensus: RERE as "Buy", EBAY as "Hold". For income investors, BACK offers the higher dividend yield at 100.00% vs EBAY's 1.08%.

MetricRERE logoREREATRenew Inc.BACK logoBACKIMAC Holdings, In…EBAY logoEBAYeBay Inc.ATXI logoATXIAvenue Therapeuti…XTLB logoXTLBXTL Biopharmaceut…
Analyst RatingConsensus buy/hold/sellBuyHold
Price TargetConsensus 12-month target$109.67
# AnalystsCovering analysts268
Dividend YieldAnnual dividend ÷ price+100.0%+1.1%
Dividend StreakConsecutive years of raises17
Dividend / ShareAnnual DPS$0.80$1.15
Buyback YieldShare repurchases ÷ mkt cap+2.5%0.0%+5.1%0.0%0.0%
Evenly matched — BACK and EBAY each lead in 1 of 2 comparable metrics.
Key Takeaway

EBAY leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RERE leads in 1 (Valuation Metrics). 2 tied.

Best OveralleBay Inc. (EBAY)Leads 3 of 6 categories
Loading custom metrics...

RERE vs BACK vs EBAY vs ATXI vs XTLB: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is RERE or BACK or EBAY or ATXI or XTLB a better buy right now?

For growth investors, ATRenew Inc.

(RERE) is the stronger pick with 25. 9% revenue growth year-over-year, versus -98. 6% for IMAC Holdings, Inc. (BACK). eBay Inc. (EBAY) offers the better valuation at 24. 5x trailing P/E (17. 4x forward), making it the more compelling value choice. Analysts rate ATRenew Inc. (RERE) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — RERE or BACK or EBAY or ATXI or XTLB?

On forward P/E, ATRenew Inc.

is actually cheaper at 1. 5x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — RERE or BACK or EBAY or ATXI or XTLB?

Over the past 5 years, eBay Inc.

(EBAY) delivered a total return of +86. 3%, compared to -100. 0% for Avenue Therapeutics, Inc. (ATXI). Over 10 years, the gap is even starker: EBAY returned +369. 5% versus ATXI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — RERE or BACK or EBAY or ATXI or XTLB?

By beta (market sensitivity over 5 years), Avenue Therapeutics, Inc.

(ATXI) is the lower-risk stock at -0. 11β versus XTL Biopharmaceuticals Ltd. 's 1. 71β — meaning XTLB is approximately -1652% more volatile than ATXI relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 160% for eBay Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — RERE or BACK or EBAY or ATXI or XTLB?

By revenue growth (latest reported year), ATRenew Inc.

(RERE) is pulling ahead at 25. 9% versus -98. 6% for IMAC Holdings, Inc. (BACK). On earnings-per-share growth, the picture is similar: Avenue Therapeutics, Inc. grew EPS 98. 8% year-over-year, compared to -5. 4% for IMAC Holdings, Inc.. Over a 3-year CAGR, RERE leads at 28. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — RERE or BACK or EBAY or ATXI or XTLB?

eBay Inc.

(EBAY) is the more profitable company, earning 18. 3% net margin versus -125. 5% for IMAC Holdings, Inc. — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EBAY leads at 20. 5% versus -78. 0% for BACK. At the gross margin level — before operating expenses — ATXI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is RERE or BACK or EBAY or ATXI or XTLB more undervalued right now?

On forward earnings alone, ATRenew Inc.

(RERE) trades at 1. 5x forward P/E versus 17. 4x for eBay Inc. — 15. 9x cheaper on a one-year earnings basis.

08

Which pays a better dividend — RERE or BACK or EBAY or ATXI or XTLB?

In this comparison, BACK (100.

0% yield), EBAY (1. 1% yield) pay a dividend. RERE, ATXI, XTLB do not pay a meaningful dividend and should not be held primarily for income.

09

Is RERE or BACK or EBAY or ATXI or XTLB better for a retirement portfolio?

For long-horizon retirement investors, IMAC Holdings, Inc.

(BACK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 05), 100. 0% yield). XTL Biopharmaceuticals Ltd. (XTLB) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BACK: -100. 0%, XTLB: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between RERE and BACK and EBAY and ATXI and XTLB?

These companies operate in different sectors (RERE (Consumer Cyclical) and BACK (Healthcare) and EBAY (Consumer Cyclical) and ATXI (Healthcare) and XTLB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RERE is a small-cap high-growth stock; BACK is a small-cap income-oriented stock; EBAY is a mid-cap quality compounder stock; ATXI is a small-cap quality compounder stock; XTLB is a small-cap quality compounder stock. BACK, EBAY pay a dividend while RERE, ATXI, XTLB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

RERE

High-Growth Disruptor

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Revenue Growth > 16%
  • Gross Margin > 12%
Run This Screen
Stocks Like

BACK

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $2B
  • Dividend Yield > 40.0%
Run This Screen
Stocks Like

EBAY

High-Growth Compounder

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Revenue Growth > 9%
  • Net Margin > 10%
Run This Screen
Stocks Like

ATXI

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 60%
Run This Screen
Stocks Like

XTLB

Quality Business

  • Sector: Healthcare
  • Market Cap > $20B
  • Gross Margin > 15%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform RERE and BACK and EBAY and ATXI and XTLB on the metrics below

Revenue Growth>
%
(RERE: 32.2% · BACK: -62.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.